

SEARCH REQUEST FORM

NOV 12 2002
Scientific and Technical Information Center

(STIC)

Requester's Full Name: Lynda Guo Examiner #: 79756 Date: 11/12/02
 Art Unit: 1651 Phone Number 30-655-1200 Serial Number: 09/979,533
 Mail Box and Bldg/Room Location: CM1-11801 Results Format Preferred (circle): PAPER DISK E-MAIL
Office: ITALO

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Method for increasing the propionate in the gastro-intestinal tract
 Inventors (please provide full names): _____

Earliest Priority Filing Date: _____

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Jan please!

Jan Delaval
 Reference Librarian
 Biotechnology & Chemical Library
 CM1 1E07 - 703-308-4498
 jan.delaval@uspto.gov

STAFF USE ONLY

Searcher: Jan
 Searcher Phone #: 4498
 Searcher Location: _____
 Date Searcher Picked Up: 11/14/02
 Date Completed: 11/14/02
 Searcher Prep & Review Time: _____
 Clerical Prep Time: 15
 Online Time: +9

Type of Search	Vendors and cost where applicable
NA Sequence (#)	STN _____
AA Sequence (#)	Dialog _____
Structure (#)	Questel/Orbit _____
Bibliographic	Dr. Link _____
Litigation	Lexis/Nexis _____
Fulltext	Sequence Systems _____
Patent Family	WWW/Internet _____
Other	Other (specify) _____

=> d his

(FILE 'HOME' ENTERED AT 07:28:54 ON 14 NOV 2002)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 07:29:05 ON 14 NOV 2002
E PROPIONIC ACID/CN
L1 1 S E3
E PROPIONATE/CN
L2 1 S E3
E DEXTRAN/CN
L3 1 S E3
L4 2 S L1,L2
SEL RN
L5 1416 S E1-E2/CRN
L6 929 S L5 NOT (MNS OR MXS OR IDS OR PMS OR AYS OR CCS)/CI
L7 530 S L6 NOT COMPD
L8 331 S L7 NOT SALT
L9 199 S L7 NOT L8
L10 15 S L9 AND NR>=1
L11 184 S L9 NOT L10
L12 186 S L4,L11
SEL RN L3
L13 931 S E3/CRN
L14 1132 S DEXTRAN
L15 1134 S L13,L14
L16 1133 S L15 NOT L3
E INULIN/CN
L17 1 S E3
E FRUCTOSE/CN
L18 2 S E3
L19 1 S L-FRUCTOSE/CN
E GALACTOSE/CN
L20 2 S E3
L21 1 S L-GALACTOSE/CN
E XYLOSE/CN
L22 2 S E3
L23 1 S L-XYLOSE/CN

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

FILE 'HCAPLUS' ENTERED AT 07:47:22 ON 14 NOV 2002
L24 19794 S L4
L25 2929 S L11
L26 68956 S PROPIONIC ACID OR PROPIONATE
L27 5679 S PROPAANOIC ACID
L28 78352 S L24-L27
L29 11735 S L3
L30 7546 S L16
L31 30359 S DEXTRAN
L32 31947 S ?DEXTRAN?
L33 33493 S L29-L32
L34 158 S L28 AND L33

FILE 'REGISTRY' ENTERED AT 07:50:44 ON 14 NOV 2002
L35 1 S CHOLESTEROL/CN

FILE 'HCAPLUS' ENTERED AT 07:50:48 ON 14 NOV 2002
L36 85119 S L35
L37 153391 S ?CHOLESTER?
L38 10311 S HYPERLIPID? OR HYPERLIPEM? OR HYPERLIPAEM?
L39 28640 S TRIGLYER? OR VLDL OR HDL OR LIPOPROTEIN(L) (VLD OR HD OR VERY

FILE 'REGISTRY' ENTERED AT 07:53:24 ON 14 NOV 2002
L40 1 S INSULIN/CN

L41 6388 S INSULIN NOT L40

FILE 'HCAPLUS' ENTERED AT 07:53:33 ON 14 NOV 2002
L42 101061 S L40 OR L41
L43 148034 S ?INSULIN?

FILE 'REGISTRY' ENTERED AT 07:53:52 ON 14 NOV 2002
L44 2 S GLUCOSE/CN

FILE 'HCAPLUS' ENTERED AT 07:53:58 ON 14 NOV 2002
L45 133720 S L44
L46 342761 S GLUCOSE
L47 35 S L34 AND L36-L39, L42, L43, L45, L46
L48 33393 S LIPOPROTEIN(L) (VERY () (LOW DENSITY OR LOW DEN OR L DENSITY OR
L49 1 S L34 AND L48
L50 35 S L47, L49
L51 2 S L3 (L) FFD/RL AND L50
L52 2 S L50 AND NUTRI?/SC, SX
L53 12 S L50 AND (L17-L23 OR INULIN OR ?FRUCTO? OR ?GALACTO? OR ?XYLO?
E SACCHARIDE/CT
E E4+ALL
L54 1628 S E1
E E3+ALL
L55 7563 S E3
E E4+ALL
E E4+ALL
L56 26460 S E4, E3, E18, E37, E38, E64
E E5+ALL
E E5+ALL
L57 39306 S E3
12 S L50 AND L54-L57
L59 20 S L51-L53, L58
L60 3 S L59 AND FATTY ACID
L61 3 S L59 AND LIPID.
L62 4 S L60, L61
SEL DN AN 2 3
L63 2 S L62 AND E1-E6
L64 31 S L50 NOT L62
SEL DN AN 4 31
L65 2 S L64 AND E7-E12
L66 4 S L63, L65 AND L24-L34, L36-L39, L42, L43, L45-L65
L67 3 S L34 AND TRIGLYCER?
L68 1 S L67 AND GASTRO INTESTINAL TRACT
L69 4 S L66, L68
E JANN A/AU
L70 13 S E3, E5
E ARRIGONI E/AU
L71 117 S E3, E8, E9
E ROCHAT F/AU
L72 19 S E3-E5, E7
E SCHMID D/AU
L73 160 S E3-E15
E BAUCHE A/AU
L74 4 S E3, E5
E NESTLE/PA, CS
L75 2322 S E3, E4
L76 2325 S NESTLE?/PA, CS
L77 1 S L50 AND L70-L76
L78 4 S L69, L77
L79 4165 S L28 AND (GASTROINTESTIN? OR GASTRO INTESTIN? OR ?INTESTIN? OR
E GASTROINTESTIN/CT
E E30+ALL
E E2+ALL

L80 551727 S E3+NT
 L81 4420 S E102+NT OR E106+NT
 E GASTROINTESTIN/CT
 E E9+ALL
 L82 3886 S E2
 E ANTICHOLESTEROL/CT
 E E4+ALL
 E E2+ALL
 L83 8108 S E5,E6,E4+NT
 L84 3567 S L28 AND L80-L83
 L85 6169 S L79,L84
 L86 319 S L85 AND CARBOHYDRATE?/SC,SX,CW
 L87 2153 S L28 AND L36-L39,L42,L43
 L88 74 S L87 AND CARBOHYDRATE?/SC,SX,CW
 L89 12 S L86,L87 AND L33
 L90 3 S L89 AND L78
 L91 9 S L89 NOT L90
 L92 34 S L85,L87 AND L33
 L93 19 S L92 NOT L50
 SEL DN AN 12
 L94 1 S E1-E3 AND L93
 L95 5 S L78,L90,L94
 SEL HIT RN

FILE 'REGISTRY' ENTERED AT 08:34:16 ON 14 NOV 2002
 L96 8 S E4-E11

=> fil reg
 FILE 'REGISTRY' ENTERED AT 08:34:42 ON 14 NOV 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 12 NOV 2002 HIGHEST RN 473382-28-4
 DICTIONARY FILE UPDATES: 12 NOV 2002 HIGHEST RN 473382-28-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d ide can tot 196

L96 ANSWER 1 OF 8 REGISTRY COPYRIGHT 2002 ACS
 RN 9042-14-2 REGISTRY
 CN Dextran, hydrogen sulfate (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN Dextran polysulfate
 CN Dextran sulfate
 CN Dextran sulfate 500
 CN Dextran sulfate 5000
 CN Dextran sulfuric acid
 CN Dextran sulphate

CN MDS-Kowa,
 CN NSC 620255
 CN PF 51
 CN PF 51 (carbohydrate)
 CN Polydextran sulfate
 CN Polyglucin, sulfate
 CN Sulfopolyglucin
 CN T 500
 DR 9057-27-6, 9063-02-9, 50935-34-7, 37271-05-9, 73075-68-0, 191288-77-4
 MF H2 O4 S . x Unspecified
 CI COM
 PCT Manual registration, Polyether, Polyether only
 LC STN Files: ADISINSIGHT, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CEN, CHEMCATS, CHEMLIST, CIN,
 CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,
 NIOSHTIC, PIRA, PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL, VTB
 (*File contains numerically searchable property data)
 Other Sources: NDSL**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)


CM 1

CRN 9004-54-0
 CMF Unspecified
 CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 7664-93-9
 CMF H2 O4 S



2477 REFERENCES IN FILE CA (1962 TO DATE)
 165 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 2482 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:299974
 REFERENCE 2: 137:293552
 REFERENCE 3: 137:293522
 REFERENCE 4: 137:293290
 REFERENCE 5: 137:289051
 REFERENCE 6: 137:284401
 REFERENCE 7: 137:284290
 REFERENCE 8: 137:276876
 REFERENCE 9: 137:243046

REFERENCE 10: 137:241444

L96 ANSWER 2 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN 9005-80-5 REGISTRY
CN Inulin (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN Alant starch
CN Alantin
CN Dahlin
CN Fibruline
CN Fibruline Instant
CN Fibruline LC
CN Fibruline Long Chain
CN Frutafit
CN Frutafit HD
CN Frutafit IQ
CN Inulin IQ
CN Inutec N 10GR
CN Raftiline
CN Raftiline GR
CN Raftiline HP
CN Raftiline LS
CN Raftiline ST
CN Sinantrin
CN Synantherin
CN Synanthrin
CN Synantrin
DR 189444-25-5
MF Unspecified
CI PMS, COM, MAN
PCT Manual registration
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,
CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN,
CSChem, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA,
MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, TOXCENTER,
USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

2463 REFERENCES IN FILE CA (1962 TO DATE)
187 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2469 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:299965

REFERENCE 2: 137:299752

REFERENCE 3: 137:288433

REFERENCE 4: 137:283981

REFERENCE 5: 137:278427

REFERENCE 6: 137:278265

REFERENCE 7: 137:278121

REFERENCE 8: 137:272957

REFERENCE 9: 137:268311

REFERENCE 10: 137:268175

L96 ANSWER 3 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN 9004-54-0 REGISTRY
CN Dextran (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Dextrans (8CI)
OTHER NAMES:
CN .alpha.-Dextran
CN 58: PN: WO0185782 FIGURE: 18 claimed sequence
CN CDC-H
CN DEX 500
CN Dextran 1.5
CN Dextran 10
CN Dextran 1000
CN Dextran 110
CN Dextran 15
CN Dextran 150
CN Dextran 2000
CN Dextran 250
CN Dextran 3000
CN Dextran 40
CN Dextran 45
CN Dextran 500
CN Dextran 60
CN Dextran 70
CN Dextran 75
CN Dextran B 512
CN Dextran B1355
CN Dextran D 10
CN Dextran PL 1S
CN Dextran PT 25
CN Dextran PVD
CN Dextran RMI
CN Dextran T 10
CN Dextran T 110
CN Dextran T 150
CN Dextran T 20
CN Dextran T 2000
CN Dextran T 500
CN Dextran T 70
CN Dextranen
CN Dextraven
CN Eudextran
CN Expandex
CN Gentran
CN Hemodex
CN Hyscon
CN Hyskon
CN Infucoll
CN Intradex
CN Intrader
CN LMD
CN LMWD
CN Longasteril 70.
CN LU 122
CN LVD
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY
DR 12626-85-6, 9013-80-3, 9044-66-0, 11104-36-2, 11121-03-2, 37224-17-2,
86280-85-5
MF Unspecified
CI PMS, COM, MAN

PCT Manual registration, Polyether, Polyether only
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, CA, CABA,
CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX,
CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, IFICDB,
IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR,
PHARMASEARCH, PIRA, PROMT, RTECS*, TOXCENTER, TULSA, USAN, USPAT2,
USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
11709 REFERENCES IN FILE CA (1962 TO DATE)
2200 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
11737 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:299981
REFERENCE 2: 137:299723
REFERENCE 3: 137:299668
REFERENCE 4: 137:296727
REFERENCE 5: 137:296464
REFERENCE 6: 137:296463
REFERENCE 7: 137:296246
REFERENCE 8: 137:296138
REFERENCE 9: 137:295451
REFERENCE 10: 137:293545

L96 ANSWER 4 OF 8 REGISTRY COPYRIGHT 2002 ACS

RN 9004-10-8 REGISTRY

CN Insulin (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Actrapid
CN Actrapid HM
CN Actrapid MC
CN Decurvon
CN Dermulin
CN Endopancrine
CN Exubera
CN HMR 4006
CN Iletin
CN Insular
CN Insulin Injection
CN Insulyl
CN Intesulin B
CN Iszilin
CN Musulin

DR 8049-67-0, 8049-95-4, 9004-12-0, 9045-63-0, 9045-65-2, 9045-66-3,
9045-67-4, 9066-39-1, 9066-40-4, 11081-38-2, 57126-42-8, 37243-75-7,
37294-43-2, 69090-47-7, 88026-11-3, 88026-12-4

MF Unspecified

CI PMS, COM, MAN

PCT Manual registration

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,
CA, CABA, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM,

CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA,
MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PDLCOM*, PHAR, PHARMASEARCH, PIRA,
PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL, VTB
(*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

81080 REFERENCES IN FILE CA (1962 TO DATE)

1487 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

81116 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:299964

REFERENCE 2: 137:299963

REFERENCE 3: 137:299954

REFERENCE 4: 137:299914

REFERENCE 5: 137:299885

REFERENCE 6: 137:299873

REFERENCE 7: 137:295256

REFERENCE 8: 137:294183

REFERENCE 9: 137:294178

REFERENCE 10: 137:294164

L96 ANSWER 5 OF 8 REGISTRY COPYRIGHT 2002 ACS

RN 79-09-4 REGISTRY

CN Propanoic acid (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Propionic acid (6CI, 8CI)

OTHER NAMES:

CN Adofeed

CN Antischim B

CN Carboxyethane

CN Ethanecarboxylic acid

CN Ethylformic acid

CN Luprosil

CN Metacetonic acid

CN Methylacetic acid

CN MonoProp

CN Propcorn

CN Propkorn

CN Prozoin

CN Pseudoacetic acid

CN Toxi-Check


FS 3D CONCORD

MF C3 H6 O2

CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS,
BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB,
CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB,
DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2,
ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB,
IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*,
PHARMASEARCH, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER,
TULSA, ULIDAT, USPAT2, USPATFULL, VTB

(*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

19350 REFERENCES IN FILE CA (1962 TO DATE)
 909 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 19388 REFERENCES IN FILE CAPLUS (1962 TO DATE)
 7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:302992

REFERENCE 2: 137:300511

REFERENCE 3: 137:299932

REFERENCE 4: 137:299395

REFERENCE 5: 137:299075

REFERENCE 6: 137:299064

REFERENCE 7: 137:298879

REFERENCE 8: 137:297042

REFERENCE 9: 137:296517

REFERENCE 10: 137:296472

L96 ANSWER 6 OF 8 REGISTRY COPYRIGHT 2002 ACS

RN 59-23-4 REGISTRY

CN D-Galactose (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Galactose, D- (8CI)

OTHER NAMES:

CN (+)-Galactose

CN D-(+)-Galactose

CN Galactose

FS STEREOSEARCH

DR 147-76-2, 3812-56-4, 400876-94-0

MF C6 H12 O6

CI COM


LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CABAB, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
 CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE,
 GMELIN*, HODQC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS,
 NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE,
 TOXCENTER, TULSA, USPAT2, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

16669 REFERENCES IN FILE CA (1962 TO DATE)
 695 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 16701 REFERENCES IN FILE CAPLUS (1962 TO DATE)
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:300027

REFERENCE 2: 137:299955

REFERENCE 3: 137:296477

REFERENCE 4: 137:295220

REFERENCE 5: 137:295189

REFERENCE 6: 137:294430

REFERENCE 7: 137:294159

REFERENCE 8: 137:293919

REFERENCE 9: 137:293899

REFERENCE 10: 137:293665

L96 ANSWER 7 OF 8 REGISTRY COPYRIGHT 2002 ACS

RN 57-88-5 REGISTRY

CN Cholest-5-en-3-ol (3. β .)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Cholesterol (8CI)

OTHER NAMES:

CN (-)-Cholesterol

CN .DELTA.5-Cholesten-3. β .-ol

CN 3. β .-Hydroxycholest-5-ene

CN 5:6-Cholesten-3. β .-ol

CN Cholest-5-en-3. β .-ol

CN Cholesterin

CN Cholesteryl alcohol

CN Dythol

CN Lidinit

CN Lidinite

CN Provitamin D

FS STEREOSEARCH

DR 209124-38-9, 218965-24-3, 378185-03-6

MF C27 H46 O

CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2,


USPATFULL, VETU, VTB

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

85113 REFERENCES IN FILE CA (1962 TO DATE)

8308 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

85183 REFERENCES IN FILE CAPLUS (1962 TO DATE)

15 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:300027

REFERENCE 2: 137:299891

REFERENCE 3: 137:299877

REFERENCE 4: 137:299733

REFERENCE 5: 137:299732

REFERENCE 6: 137:299715

REFERENCE 7: 137:299706

REFERENCE 8: 137:299702

REFERENCE 9: 137:299696

REFERENCE 10: 137:299674

L96 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2002 ACS

RN 50-99-7 REGISTRY

CN D-Glucose (8CI, 9CI) (CA INDEX NAME)

OTHER NAMES:

CN (+)-Glucose

CN Anhydrous dextrose.

CN Cartose

CN Cerelose

CN Cerelose 2001

CN Corn sugar

CN D(+)-Glucose

CN Dextropur


CN Dextrose

CN Dextrosol

CN Glucolin

CN Glucose
 CN Glucosteril
 CN Goldsugar
 CN Grape sugar
 CN Maxim Energy Gel
 CN Roferose ST
 CN Staleydex 111
 CN Staleydex 333
 CN Sugar, grape
 CN Tabfine 097 (HS)
 CN Vadex
 FS STEREOSEARCH
 DR 8012-24-6, 8030-23-7, 162222-91-5, 165659-51-8, 50933-92-1, 80206-31-1
 MF C6 H12 O6
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS,
 BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB,
 CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB,
 DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB,
 IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC,
 PDLCOM*, PHARMASEARCH, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA,
 ULIDAT, USAN, USPAT2, USPATFULL, VETU, VTB
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

133561 REFERENCES IN FILE CA (1962 TO DATE)
 2016 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 133673 REFERENCES IN FILE CAPLUS (1962 TO DATE)
 14 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:303955
 REFERENCE 2: 137:301291
 REFERENCE 3: 137:301282
 REFERENCE 4: 137:300521
 REFERENCE 5: 137:300332
 REFERENCE 6: 137:300027
 REFERENCE 7: 137:299968
 REFERENCE 8: 137:299955
 REFERENCE 9: 137:299937
 REFERENCE 10: 137:299913

=> fil hcplus
FILE 'HCAPLUS' ENTERED AT 08:34:58 ON 14 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Nov 2002 VOL 137 ISS 20
FILE LAST UPDATED: 13 Nov 2002 (20021113/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d all tot 195 hitstr

L95	ANSWER 1 OF 5	HCAPLUS	COPYRIGHT 2002 ACS																																																		
AN	2002:293417	HCAPLUS																																																			
DN	136:315003																																																				
TI	Particulate bulking agents for medicinal aerosol formulations																																																				
IN	Jinks, Philip A.; McKenzie, Lesley; Lister, James T.																																																				
PA	3M Innovative Properties Company, USA																																																				
SO	PCT Int. Appl., 27 pp.																																																				
	CODEN: PIXXD2																																																				
DT	Patent																																																				
LA	English																																																				
IC	ICM A61K009-00																																																				
CC	63-6 (Pharmaceuticals)																																																				
FAN.CNT	1																																																				
<table border="0"> <thead> <tr> <th>PATENT NO.</th> <th>KIND</th> <th>DATE</th> <th>APPLICATION NO.</th> <th>DATE</th> </tr> </thead> <tbody> <tr> <td>-----</td> <td>-----</td> <td>-----</td> <td>-----</td> <td>-----</td> </tr> <tr> <td>PI WO 2002030394</td> <td>A2</td> <td>20020418</td> <td>WO 2001-US30575</td> <td>20011001</td> </tr> <tr> <td>W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>AU 2002011311</td> <td>A5</td> <td>20020422</td> <td>AU 2002-11311</td> <td>20011001</td> </tr> <tr> <td>PRAI GB 2000-24711</td> <td>A</td> <td>20001009</td> <td></td> <td></td> </tr> <tr> <td>GB 2001-22512</td> <td>A</td> <td>20010918</td> <td></td> <td></td> </tr> <tr> <td>WO 2001-US30575</td> <td>W</td> <td>20011001</td> <td></td> <td></td> </tr> <tr> <td>AB</td> <td colspan="4">Use of particulate bulking agents having an extremely small mass median</td> </tr> </tbody> </table>				PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	-----	-----	-----	-----	-----	PI WO 2002030394	A2	20020418	WO 2001-US30575	20011001	W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU					RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					AU 2002011311	A5	20020422	AU 2002-11311	20011001	PRAI GB 2000-24711	A	20001009			GB 2001-22512	A	20010918			WO 2001-US30575	W	20011001			AB	Use of particulate bulking agents having an extremely small mass median			
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE																																																	
-----	-----	-----	-----	-----																																																	
PI WO 2002030394	A2	20020418	WO 2001-US30575	20011001																																																	
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU																																																					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG																																																					
AU 2002011311	A5	20020422	AU 2002-11311	20011001																																																	
PRAI GB 2000-24711	A	20001009																																																			
GB 2001-22512	A	20010918																																																			
WO 2001-US30575	W	20011001																																																			
AB	Use of particulate bulking agents having an extremely small mass median																																																				

diam. of, less than one micron, preferably less than 300 nm, in pharmaceutical aerosol formulations comprising a suspension of drug particles in a propellant. Examples of bulking agents include ascorbic acid, saccharides, polysaccharides, amino acids, org. and inorg. salts, urea, and propyliodone. .alpha.-Lactose monohydrate was micronized and dispersed in anhyd. ethanol and homogenized.

ST pharmaceutical aerosol bulking agent

IT Drug delivery systems
(aerosols; particulate bulking agents for medicinal aerosol formulations)

IT Alkanes, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fluoro; particulate bulking agents for medicinal aerosol formulations)

IT Polyesters, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lactic acid-based; particulate bulking agents for medicinal aerosol formulations)

IT Particle size
Propellants (sprays and foams)
Surfactants
(particulate bulking agents for medicinal aerosol formulations)

IT 9004-34-6, Cellulose, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modified; particulate bulking agents for medicinal aerosol formulations)

IT 64044-51-5, Lactose monohydrate
RL: MOA (Modifier or additive use); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(particulate bulking agents for medicinal aerosol formulations)

IT 50-81-7, Ascorbic acid, biological studies 50-99-7, D-Glucose, biological studies 56-40-6, Glycine, biological studies 57-13-6, Urea, biological studies 57-50-1, Sucrose, biological studies 59-23-4, D-Galactose, biological studies 63-42-3, Lactose 69-79-4, Maltose 112-80-1, Oleic acid, biological studies 128-44-9, Sodium saccharin 302-72-7, Alanine 431-89-0, HFA 227 471-34-1, Calcium carbonate, biological studies 587-61-1, Propyliodone 811-97-2, HFA 134a 814-80-2, Calcium lactate 6138-23-4, .alpha.-D-Glucopyranoside, .alpha.-D-glucopyranosyl, dihydrate 7647-14-5, Sodium chloride, biological studies 9004-53-9, Dextrin 9004-54-0, Dextran, biological studies 9005-25-8, Starch, biological studies 14475-11-7, Sodium tartrate 17629-30-0, D-Raffinose pentahydrate 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26100-51-6, Polylactic acid 26266-58-0, Sorbitan trioleate
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(particulate bulking agents for medicinal aerosol formulations)

IT 43229-80-7, Formoterol fumarate 51022-70-9, Salbutamol sulfate
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(particulate bulking agents for medicinal aerosol formulations)

IT 60205-81-4, Ipratropium 72332-33-3, Procaterol 73573-87-2, Formoterol 80474-14-2, Fluticasone propionate 89365-50-4, Salmeterol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(particulate bulking agents for medicinal aerosol formulations)


IT 50-99-7, D-Glucose, biological studies 59-23-4
, D-Galactose, biological studies 9004-54-0,
Dextran, biological studies

RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (particulate bulking agents for medicinal aerosol formulations)

RN 50-99-7 HCPLUS

CN D-Glucose (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 59-23-4 HCPLUS

CN D-Galactose (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 9004-54-0 HCPLUS

CN Dextran (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L95 ANSWER 2 OF 5 HCPLUS COPYRIGHT 2002 ACS

AN 2001:833060 HCPLUS

DN 135:376741

TI Stable metal ion-lipid powdered pharmaceutical compositions

IN Dellamary, Luis A.; Riess, Jean; Schutt, Ernest G.; Weers, Jeffry G.; Tarara, Thomas E.

PA Alliance Pharmaceutical Corp., USA

SO PCT Int. Appl., 42 pp.
 CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-00

CC 63-6 (Pharmaceuticals)

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001085137	A2	20011115	WO 2001-US14824	20010508
	WO 2001085137	A3	20020418		
	W:	AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2000-568818	A	20000510		

- AB Microparticle compns. comprising metal ion-lipid complexes for drug delivery are described including methods of making the microparticle compns. and methods of treating certain conditions and disease states by administering the microparticle compns. The metal ion-lipid complexes can be combined with various drugs or active agents for therapeutic administration. The microparticle compns. of the present invention have superior stability to other microparticle compns. resulting in a microparticle compn. with longer shelf life and improved dispersibility. The microparticle compns. of the present invention have a transition temp. (T_m) of at least 20.degree. above the recommended storage temp. (T_{st}) for drug delivery. An aq. prepn. was prep'd. by mixing two preps., A and B, immediately prior to spray drying. The prepn. A was comprised of a fluorocarbon-in-water emulsion in which 26 g perfluoroctyl bromide was dispersed in 33 g water with the aid of 1.30 g of SPC-3 emulsifier (hydrogenated soy phosphatidylcholine). The prepn. B contained 0.162 g CaCl₂.2H₂O and 0.162 g budesonide dissolved/suspended in 4 g water. The resulting microparticle of the sample had a PL-budesonide-CaCl₂.2H₂O wt. ratio of about 80:10:10. The mean vol. aerodynamic particle size of the dry powder was approx. 4.1 .mu.m.
- ST metal phospholipid powder pharmaceutical
- IT Drug delivery systems
(aerosols; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(block; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Ribozymes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(deoxy; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Oligonucleotides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dinucleotides; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Phosphatidylcholines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(egg yolk; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Glycerophospholipids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogenated; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Anemia (disease)
(inhibitors; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Drug delivery systems
(injections, i.m.; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Drug delivery systems
(injections, i.p.; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Drug delivery systems
(injections, i.v.; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Drug delivery systems
(injections, s.c.; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Drug delivery systems
(intratracheal; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Polyesters, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lactide; stable metal ion-lipid powd. pharmaceutical compns.)

- IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(metal salts; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Drug delivery systems
(microparticles; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Antibodies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Drug delivery systems
(nasal; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Drug delivery systems
(ophthalmic; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Carotenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oxy; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phenolic; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Phospholipids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polymers; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Phenolic resins, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyoxyalkylene-; stable metal ion-lipid powd.
pharmaceutical compns.)
- IT Drug delivery systems
(powders, inhalants; stable metal ion-lipid powd.
pharmaceutical compns.)
- IT Phosphatidylcholines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soya, hydrogenated; stable metal ion-lipid powd.
pharmaceutical compns.)
- IT Phosphatidylcholines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soya; stable metal ion-lipid powd. pharmaceutical compns.)
- IT Allergy inhibitors
 - Analgesics
 - Anti-inflammatory agents
 - Antibiotics
 - Antihistamines
 - Antimigraine agents
 - Antioxidants
 - Antitumor agents
 - Bronchodilators
 - Cardiovascular agents
 - Cholinergic antagonists
 - Density
 - Fungicides
 - Gene therapy
 - Imaging agents
 - Leukotriene antagonists
 - Particle size distribution
 - Plasticizers
 - Pulmonary surfactant
 - Tuberculostatics
 - Wetting agents
(stable metal ion-lipid powd. pharmaceutical compns.)

IT Actinides
 Agglutinins and Lectins
 Albumins, biological studies
 Caseins, biological studies
 Enzymes, biological studies
 Immunoglobulins
 Lipids, biological studies
 Ovalbumin
 Peptides, biological studies
 Phospholipids, biological studies
 Polyesters, biological studies
 Polyoxyalkylenes, biological studies
 Polyoxyalkylenes, biological studies
 Polysaccharides, biological studies
 Proteins, general, biological studies
 Rare earth metals, biological studies
 Ribozymes
 Salts, biological studies
 Steroids, biological studies
 Tocopherols
 Transition metals, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (stable metal ion-lipid powd. pharmaceutical compns.)

IT Drug delivery systems
 (topical; stable metal ion-lipid powd. pharmaceutical compns.)

IT Drug delivery systems
 (vaginal; stable metal ion-lipid powd. pharmaceutical compns.)

IT 50-02-2, Dexamethasone 57-50-1, Sucrose, biological studies 63-42-3,
 Lactose 69-65-8, Mannitol 74-55-5, Ethambutol 76-25-5, Triamcinolone
 acetonide 99-20-7, Trehalose 110-01-0, THT 128-37-0, BHT, biological
 studies 471-34-1, Calcium carbonate, biological studies 1403-66-3,
 Gentamicin 1405-41-0, Gentamicin sulfate 2644-64-6, DPPC 3458-28-4,
 Mannose 4539-70-2, DSPC 5534-09-8, Beclomethasone dipropionate
 7429-90-5, Aluminum, biological studies 7439-89-6, Iron, biological
 studies 7439-95-4, Magnesium, biological studies 7440-66-6, Zinc,
 biological studies 7440-70-2, Calcium, biological studies 7786-30-3,
 Magnesium chloride (MgCl₂), biological studies 9002-89-5, Poly(vinyl
 alcohol) 9003-01-4, Poly(acrylic acid) 9003-01-4D, Poly(acrylic acid),
 salts 9003-39-8, PVP 9004-10-8, **Insulin**, biological
 studies 9004-32-4, Carboxymethyl cellulose 9004-34-6D, Cellulose,
 esters, biological studies 9004-54-0, **Dextran**,
 biological studies 9005-25-8, Starch, biological studies 9005-25-8D,
 Starch, derivs., biological studies 9005-27-0, Hydroxyethyl starch
9005-80-5, **Inulin** 9012-76-4, Chitosan 9012-76-4D,
 Chitosan, derivs. 9042-14-2, **Dextran** sulfate
 9072-56-4, Starch ethyl ether 10043-52-4, Calcium chloride (CaCl₂),
 biological studies 12619-70-4, Cyclodextrin 12633-72-6, Amphotericin
 15687-27-1, Ibuprofen 18559-94-9, Albuterol 18656-38-7, DMPC
 21361-93-3 25104-18-1, Poly(L-lysine) 25191-17-7, Poly(L-alanine)
 25213-34-7, Poly(L-alanine) 25301-02-4, Tyloxapol 25322-68-3,
 Polyethylene glycol 25718-94-9, Polyglycine 25734-27-4, Polyglycine
 26009-03-0, Polyglycolide 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-
 ethanediyl)] 26202-08-4, Polyglycolide 26680-10-4, Polylactide
 32986-56-4, Tobramycin 33069-62-4, Taxol 37189-22-3, Starch methyl
 ether 37353-59-6, Hydroxymethyl cellulose 37517-28-5, Amikacin
 38000-06-5, Poly(L-lysine) 41017-85-0 43229-80-7, Formoterol fumarate
 51293-66-4 51333-22-3, Budesonide 61230-46-4 80474-14-2, Fluticasone
propionate 93107-08-5, Ciprofloxacin hydrochloride 94749-08-3,
 Salmeterol xinafoate 95188-93-5 106392-12-5, Poloxamer 110617-70-4,
 Poloxamine 114466-38-5, Sermorelin acetate 143831-71-4, Pulmozyme
 352466-80-9, Tobramycin nitrate 373598-27-7 373598-29-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (stable metal ion-lipid powd. pharmaceutical compns.)
 IT 9004-10-8, Insulin, biological studies 9004-54-0
 , Dextran, biological studies 9005-80-5,
 Inulin 9042-14-2, Dextran sulfate
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (stable metal ion-lipid powd. pharmaceutical compns.)
 RN 9004-10-8 HCPLUS
 CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9004-54-0 HCPLUS
 CN Dextran (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9005-80-5 HCPLUS
 CN Inulin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9042-14-2 HCPLUS
 CN Dextran, hydrogen sulfate (9CI) (CA INDEX NAME)


CM 1

CRN 9004-54-0
 CMF Unspecified
 CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 7664-93-9
 CMF H₂O₄S



L95 ANSWER 3 OF 5 HCPLUS COPYRIGHT 2002 ACS
 AN 2000:841932 HCPLUS
 DN 133:362265
 TI Method for increasing propionate in the gastro-
 intestinal tract
 IN Jann, Alfred; Arrigoni, Eva; Rochat, Florence
 ; Schmid, Daniel; Bauche, Anne
 PA Societe des Produits Nestle S. A., Switz.
 SO PCT Int. Appl., 16 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A23L001-054
 ICS A23L001-308; A23L001-30
 CC 18-4 (Animal Nutrition)
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI WO 2000070964	A1	20001130	WO 2000-EP4744	20000519

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1060673 A1 20001220 EP 1999-109916 19990520

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRAI EP 1999-109916 A 19990520

AB A method for selectively increasing the prodn. of **propionate** in the **gastro-intestinal tract** of a mammal.

The method includes the step of enterally administering to the mammal a nutritional compn. which contains **dextran**. Increasing the **propionate** prodn. results in decreased blood **cholesterol** levels, decreased blood **triglyceride** levels, decreased very low d. **lipoprotein** levels, increased high d. **lipoprotein** levels, and increased **insulin** sensitivity.

ST digestive tract **propionate** diet **dextran**; lipid blood digestive tract **propionate** diet **dextran**; lipoprotein blood digestive tract **propionate** diet **dextran**; **cholesterol** blood digestive tract **propionate** diet **dextran**; **insulin** sensitivity digestive tract **propionate** diet **dextran**

IT **Lipoproteins**

RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)

(high-d.; method for increasing **propionate** in the gastrointestinal tract)

IT **Anticholesteremic agents**

Digestive tract content

(method for increasing **propionate** in the gastrointestinal tract)

IT **Glycerides, biological studies**

RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)

(method for increasing **propionate** in the gastrointestinal tract)

IT **Fructooligosaccharides**

Galactooligosaccharides

Lipids, biological studies

Xylooligosaccharides

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method for increasing **propionate** in the gastrointestinal tract)

IT **Fatty acids, biological studies**

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(monounsatd.; method for increasing **propionate** in the gastrointestinal tract)

IT **Lipoproteins**

RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)

(very-low-d.; method for increasing **propionate** in the gastrointestinal tract)

- IT 57-88-5, Cholest-5-en-3-ol (3. β .)-, biological studies
 RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 (blood; method for increasing **propionate** in the gastrointestinal tract)
- IT 79-09-4, Propionic acid, biological studies
 RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 (method for increasing **propionate** in the gastrointestinal tract)
- IT 9004-10-8, Insulin, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (method for increasing **propionate** in the gastrointestinal tract)
- IT 9004-54-0, Dextran, biological studies 9005-80-5
 , Inulin 187112-48-7, Raftilose
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (method for increasing **propionate** in the gastrointestinal tract)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; PATENT ABSTRACTS OF JAPAN 1986, V010(043), PC-329
- (2) Fisons; EP 0153013 A 1985 HCPLUS
- (3) Hayashibara; EP 0382355 A 1990 HCPLUS
- (4) MC Cormick, D; ANNUAL REVIEWS P117
- (5) Meitou Sangyo Kk; JP 60190717 A 1985 HCPLUS
- (6) Nestle; EP 0881283 A 1998 HCPLUS
- (7) Southgate, D; Dietary Fibre:Chemical and biological Aspects 1990, P340


- IT 57-88-5, Cholest-5-en-3-ol (3. β .)-, biological studies
 RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)

(blood; method for increasing **propionate** in the gastrointestinal tract)

RN 57-88-5 HCPLUS


CN Cholest-5-en-3-ol (3. β .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



- IT 79-09-4, Propionic acid, biological studies
 RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 (method for increasing **propionate** in the gastrointestinal tract)
- RN 79-09-4 HCPLUS

CN Propanoic acid (9CI) (CA INDEX NAME)



IT 9004-10-8, Insulin, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)
 (method for increasing **propionate** in the gastrointestinal tract)

RN 9004-10-8 HCPLUS

CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9004-54-0, Dextran, biological studies 9005-80-5
 , Inulin

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (method for increasing **propionate** in the gastrointestinal tract)

RN 9004-54-0 HCPLUS

CN Dextran (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9005-80-5 HCPLUS

CN Inulin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L95 ANSWER 4 OF 5 HCPLUS COPYRIGHT 2002 ACS

AN 1993:154578 HCPLUS

DN 118:154578

TI Prolonged-release oral pharmaceutical forms containing active substances having a solubility dependent upon the pH value

IN Conte, Ubaldo; Giunchedi, Paolo

PA L.C. Pharchem Ltd., Cyprus

SO PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-16

ICS A61K009-20

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9300889	A1	19930121	WO 1992-EP1503	19920703
	W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	AU 9222293	A1	19930211	AU 1992-22293	19920703
	CN 1082888	A	19940302	CN 1992-111078	19920824
PRAI	IT 1991-MI1880		19910708		
	WO 1992-EP1503		19920703		
AB	Oral formulations comprise a weakly-basic drug (dipyridamole, cinnarizine, ketanserin) a swellable polymer and a gastroresistant polymer, carried in a gellable hydrophilic or lipophilic matrix. The swellable polymer is crosslinked Na CMC or PVC, carboxymethylstarch, PVA, etc. The gastroresistant polymer is a cellulose deriv. or acrylic polymer.				

Pellets were made of dipyridamole 50, cellulose acetate trimellitate 100, and crosslinked Na CMC 50 g. the pellets were labeled with hydroxypropylmethyl cellulose, Mg stearate and colloidal silica. The formulations release the drug at the same rate in both **gastric** and enteric environments.

ST oral drug sustained release **gastric** enteral
 IT Acrylic polymers, biological studies
 Zeins
 RL: BIOL (Biological study)
 (oral drug formulations contg., **gastro-** and entero-sol.)
 IT Pharmaceutical dosage forms
 (oral, sustained-release, **gastro-** and entero-sol.)
 IT 9002-89-5 9003-39-8D, Polyvinylpyrrolidone, crosslinked 9004-32-4D, Sodium carboxymethylcellulose, crosslinked 9004-34-6D, Cellulose, derivs. 9004-38-0, Cellulose acetate phthalate 9004-39-1, Cellulose acetate propionate 9004-54-0D, **Dextran**, derivs. 9005-25-8D, Starch, derivs. 9012-72-0D, Glucan, derivs. 9057-06-1, Carboxymethyl starch 52907-01-4, Cellulose acetate trimellitate 65405-55-2, Potassium methacrylate-divinylbenzene copolymer
 RL: BIOL (Biological study)
 (oral drug formulations contg., **gastro-** and entero-sol.)
 IT 58-32-2, Dipyridamole 298-57-7, Cinnarizine 74050-98-9, Ketanserin
 RL: BIOL (Biological study)
 (oral formulations contg., **gastro-** and entero-sol.)
 IT 9004-54-0D, **Dextran**, derivs.
 RL: BIOL (Biological study)
 (oral drug formulations contg., **gastro-** and entero-sol.)
 RN 9004-54-0 HCPLUS
 CN Dextran (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L95 ANSWER 5 OF 5 HCPLUS COPYRIGHT 2002 ACS
 AN 1966:414823 HCPLUS
 DN 65:14823
 OREF 65:2782d-g
 TI Disturbance of the fatty acid metabolism of arteriosclerosis and its treatment
 AU Aizawa, Toyozo; Goto, Yuichiro; Katayama, Tetsuji; Nakamura, Haruo; Hori, Sadaaki; Tatsuzawa, Yasushi
 CS Keio Univ., Tokyo
 SO Proc. Asian-Pacific Congr. Cardiol., 3rd, Kyoto (1964), (1), 611-15
 DT Journal
 LA English
 CC 66 (Mammalian Pathological Biochemistry)
 AB **Cholesterol** level and fatty acid (FA) compn. in plasma was not changed appreciably by age or sex in the normal group under 39 years old. A slightly higher percentage of linoleic acid (I) was observed in women. In normal persons over 40, there was no significant change in either **cholesterol** or FA compn. due to age or sex. Hypertensive patients showed slightly higher palmitic acid (II) and oleic acid (III) concns., with I slightly lower than normal. Arteriosclerotics showed a significant increase in II and III, and a significant decrease in I. **Cholesterol** esters had a higher percentage of I in normal young women than in men. Neutral fat, phospholipid, and nonesterified FA in arteriosclerotics showed higher II and III with lower I content than normal. Various **hypcholesterolemic** agents were tested for alteration of the plasma FA compn. MER-29 (an inhibitor of **cholesterol** synthesis), TBF-43 (a synthetic thyroxine deriv.), and atromid decreased the **cholesterol** level markedly, but had no effect on un balanced FA compn. Ethynodiol, p-tolyl methyl carbinol, neomycin, **dextran** sulfate, and pyridoxal phosphate decreased the **cholesterol** slightly, but did not improve the FA compn. Nicotinic

acid reduced **cholesterol**, but increased II and III while decreasing I. Ateroid (a heparinoid) had no effect on **cholesterol** or FA compn. .alpha.-Tocopherol decreased **cholesterol** only slightly, but improved the FA compn. slightly. 3-Deoxyesterone decreased **cholesterol** and slightly improved the FA compn. Et linoleate was administered to 12 patients and reduced **cholesterol** and neutral fat, and improved the FA compn. of **cholesterol** ester, neutral fat, and phospholipid. The percentage of I increased moderately. The FA pattern in arteriosclerotic patients would be improved if **hypcholesterolemic** agents were administered with I.

- IT Arteriosclerosis
 - (fatty acid metabolism in, therapy and)
- IT Blood pressure
 - (high, fatty acid metabolism in, arteriosclerosis and)
- IT Fats
 - (in blood plasma in arteriosclerosis, therapy and)
- IT Phospholipids
 - (in blood plasma, in arteriosclerosis, therapy and)
- IT Blood plasma
 - (lincomycin in, milk and)
- IT Fatty acids
 - (metabolism of, in arteriosclerosis, therapy and)
- IT 2,8-dimethyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-,
 - 2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-
 - (fatty acid metabolism in arteriosclerosis)
- IT Cholesterol, esters of
 - (in atherosclerosis, linoleic acid in)
- IT Cholesterol, esters of
 - (in blood plasma in arteriosclerosis, therapy and)
- IT Blood corpuscles, red.
 - (linoleic acid in, in atherosclerosis)
- IT 53-45-2, Estra-1,3,5(10)-trien-17-one 54-47-7, Pyridoxal, 5-phosphate 78-41-1, Ethanol, 2-(p-chlorophenyl)-1-[p-[2-(diethylamino)ethoxy]phenyl]-1-p-tolyl- 536-50-5, Benzyl alcohol, p,.alpha.-dimethyl- 544-35-4, Linoleic acid, ethyl ester 637-07-0, Propionic acid, 2-(p-chlorophenoxy)-2-methyl-, ethyl ester 965-90-2, Ethylnandrol 1160-36-7, Benzoic acid, 4-(4-acetyl-3-iodophenoxy)-3,5-diido- 1404-04-2, Neomycins 9010-06-4, Ateroid
 - (fatty acid metabolism in arteriosclerosis after treatment with)
- IT 57-88-5, Cholesterol 60-33-3, Linoleic acid
 - (in blood plasma, in arteriosclerosis, therapy and)
- IT 59-67-6, Nicotinic acid
 - (in fatty acid metabolism, in arteriosclerosis)
- IT 57-10-3, Palmitic acid 112-80-1, Oleic acid
 - (metabolism of, in arteriosclerosis, therapy and)
- IT 9004-54-0, Dextrans
 - (sulfates, fatty acid metabolism in arteriosclerosis after treatment with)
- IT 57-88-5, Cholesterol
 - (in blood plasma, in arteriosclerosis, therapy and)
- RN 57-88-5 HCPLUS
- CN Cholest-5-en-3-ol (3.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 9004-54-0, **Dextrans**

(sulfates, fatty acid metabolism in arteriosclerosis after treatment with)

RN 9004-54-0 HCPLUS

CN Dextran (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=> fil medline

FILE 'MEDLINE' ENTERED AT 08:58:41 ON 14 NOV 2002

FILE LAST UPDATED: 13 NOV 2002 (20021113/UP). FILE COVERS 1958 TO DATE.

On June 9, 2002, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2002 vocabulary. Enter HELP THESAURUS for details.

If you received SDI results from MEDLINE on October 8, 2002, these may have included old POPLINE data and in some cases duplicate abstracts. For further information on this situation, please visit NLM at:
http://www.nlm.nih.gov/pubs/techbull/so02/so02_popline.html

To correct this problem, CAS will remove the POPLINE records from the MEDLINE file and process the SDI run dated October 8, 2002 again.

Customers who received SDI results via email or hard copy prints on October 8, 2002 will not be charged for this SDI run. If you received your update online and displayed answers, you may request a credit by contacting the CAS Help Desk at 1-800-848-6533 in North America or 614-447-3698 worldwide, or via email to help@cas.org

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all tot

L112 ANSWER 1 OF 2 MEDLINE

AN 95017698 MEDLINE

DN 95017698 PubMed ID: 7523661

TI Functional role of bicarbonate in propionate transport across guinea-pig isolated caecum and proximal colon.

AU von Engelhardt W; Gros G; Burmester M; Hansen K; Becker G; Rechkemmer G

CS Department of Physiology, School of Veterinary Medicine, Hannover, Germany.

SO JOURNAL OF PHYSIOLOGY, (1994 Jun 1) 477 (Pt 2) 365-71.
 Journal code: 0266262. ISSN: 0022-3751.

CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199411
 ED Entered STN: 19941222
 Last Updated on STN: 19960129
 Entered Medline: 19941110
 AB 1. Unidirectional fluxes of **propionate** across isolated epithelia from the guinea-pig caecum and proximal colon were measured under short-circuit current conditions. In the caecum and proximal colon the serosal-to-mucosal **propionate** flux (JPrsm) was higher than mucosal-to-serosal flux (JPrms), resulting in a net secretory flux of **propionate**. 2. HCO₃(-)–CO₂-free solution reduced JPrms in the caecum and proximal colon markedly; JPrsm was not (caecum) or little (proximal colon) affected. The subsequent addition of acetazolamide caused a further decrease in JPrms in the proximal colon, but not in the caecum. 3. In HCO₃(-)–containing solutions acetazolamide or ethoxzolamide inhibited JPrms; JPrsm was not affected. A macromolecular carbonic anhydrase inhibitor, prontosil-**dextran**, had no effect on **propionate** fluxes, indicating that the intracellular carbonic anhydrase is of importance for short-chain fatty acid transport. 4. Subsequent to carbonic anhydrase inhibition, mucosal addition of amiloride caused a slight further decrease of JPrms in the caecum and proximal colon; JPrsm was not affected. 5. Results support the view that a considerable proportion of short-chain fatty acids (SCFAs) is absorbed via a SCFA(–)-HCO₃[–] exchange.
 CT Check Tags: Animal; Male; Support, Non-U.S. Gov't
 Acetazolamide: PD, pharmacology
 *Bicarbonates: ME, metabolism
 Carbonic Anhydrases: ME, metabolism
 Cecum: DE, drug effects
 *Cecum: ME, metabolism
 Colon: DE, drug effects
 *Colon: ME, metabolism
 Dextrans: PD, pharmacology
 Ethoxzolamide: PD, pharmacology
 Guinea Pigs
 Intestinal Mucosa: DE, drug effects
 *Intestinal Mucosa: ME, metabolism
 Ion Transport: DE, drug effects
 *Propionates: ME, metabolism
 p-Aminoazobenzene: AA, analogs & derivatives
 p-Aminoazobenzene: PD, pharmacology
 RN 103-12-8 (sulfamidochrysoidine); 452-35-7 (Ethoxzolamide); 59-66-5 (Acetazolamide); 60-09-3 (p-Aminoazobenzene); 9004-54-0 (**Dextrans**)
 CN 0 (Bicarbonates); 0 (**Propionates**); EC 4.2.1.1 (Carbonic Anhydrases)

L112 ANSWER 2 OF 2 MEDLINE
 AN 71234310 MEDLINE
 DN 71234310 PubMed ID: 4933388
 TI Combined use of clofibrate and cholestyramine or DEAE sephadex in hypercholesterolaemia.
 AU Howard A N; Hyams D E
 SO BRITISH MEDICAL JOURNAL, (1971 Jul 3) 3 (765) 25-7.
 Journal code: 0372673. ISSN: 0007-1447.
 CY ENGLAND: United Kingdom
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals

EM 197108 .
 ED Entered STN: 19900101
 Last Updated on STN: 19900101
 Entered Medline: 19710821
 CT Check Tags: Comparative Study; Human
 *Anticholesteremic Agents: TU, therapeutic use
 Cholesterol: BL, blood
 Cholestyramine: AE, adverse effects
 *Cholestyramine: TU, therapeutic use
 Clinical Trials
 Clofibrate: TU, therapeutic use
 Constipation: CI, chemically induced
 *Dextran: TU, therapeutic use
 Drug Synergism
 *Hypercholesterolemia: DT, drug therapy
 *Propionates: TU, therapeutic use
 RN 11041-12-6 (Cholestyramine); 57-88-5 (Cholesterol); 637-07-0 (Clofibrate);
 9004-54-0 (Dextran)
 CN 0 (Anticholesteremic Agents); 0 (Propionates)

=> fil wpix
 FILE 'WPIX' ENTERED AT 09:11:28 ON 14 NOV 2002
 COPYRIGHT (C) 2002 THOMSON DERWENT

FILE LAST UPDATED: 13 NOV 2002 <20021113/UP>
 MOST RECENT DERWENT UPDATE: 200273 <200273/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> SLART (Simultaneous Left and Right Truncation) is now
 available in the /ABEX field. An additional search field
 /BIX is also provided which comprises both /BI and /ABEX <<<

>>> PATENT IMAGES AVAILABLE FOR PRINT AND DISPLAY <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,
 SEE <http://www.derwent.com/dwpi/updates/dwpicov/index.html> <<<

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
 PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
 GUIDES, PLEASE VISIT:
http://www.derwent.com/userguides/dwpi_guide.html <<<

=> d all abeq tech abex tot

L130 ANSWER 1 OF 3 WPIX (C) 2002 THOMSON DERWENT
 AN 2001-049855 [06] WPIX
 DNC C2001-013691
 TI Use of **dextran** to selectively increase mammalian
 gastrointestinal **propionate** production, useful for nutritional
 compositions e.g. for reducing blood cholesterol levels.
 DC B04 D13
 IN ARRIGONI, E; JANN, A; ROCHAT, F; SCHMID, D; BAUCHE, A
 PA (NEST) SOC PROD NESTLE SA
 CYC 92
 PI WO 2000070964 A1 20001130 (200106)* EN 17p A23L001-054 <--
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
 NL OA PT SD SE SL SZ TZ UG ZW
 W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES
 FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS

LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL
 TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
 EP 1060673 A1 20001220 (200106) EN A23L001-054 <--
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI
 AU 2000059689 A 20001212 (200115) A23L001-054 <--
 ADT WO 2000070964 A1 WO 2000-EP4744 20000519; EP 1060673 A1 EP 1999-109916
 19990520; AU 2000059689 A AU 2000-59689 20000519
 FDT AU 2000059689 A Based on WO 200070964
 PRAI EP 1999-109916 19990520
 IC ICM A23L001-054
 ICS A23L001-30; A23L001-308
 AB WO 200070964 A UPAB: 20010126
 NOVELTY - The use of **dextran** in nutritional compositions that selectively increase **propionate** production in the mammalian gastrointestinal tract, is new.
 DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the use of **dextran** in nutritional compositions that decrease mammalian blood levels of cholesterol, triglycerides, very low density lipoproteins, high density lipoproteins, and that decrease insulin sensitivity.
 ACTIVITY - Anorectic; antilipemic.
 MECHANISM OF ACTION - Dietary supplement; blood-lipid reducer; insulin desensitizer. **Dextran** is a substrate for fermentation by gut commensal micro-organisms. The fermentation produces **propionate** that has the lipid-lowering and insulin-desensitizing properties. Four volunteers in a double-blind cross-over study to evaluate the effect of **dextran** on **propionate** production. This was determined through measuring fecal concentrations **propionic acid**. Giving **Dextran** T2000 (15 g) acutely increased the **propionic acid** concentration in the test group by 3.43 mM compared with the control. A chronic dose of 10 g/day for a week gave an increase of 24 micro M/g dry feces in the treatment group and a decrease of 5.7 micro M/g dry feces in the control group.
 USE - The **dextran** is useful for making nutritional compositions that increase **propionate** production in the mammalian gastrointestinal tract thereby decreased blood levels of cholesterol, triglycerides, very low density lipoproteins, high density lipoproteins, and decreasing insulin sensitivity.
 ADVANTAGE - **Dextran** produces more **propionate** than other non-digestible polysaccharides in the mammalian gastrointestinal tract.
 Dwg.0/0
 FS CPI
 FA AB; DCN
 MC CPI: B01-D02; B04-C02C; B04-C02X; B10-G02; B12-M07; B14-D01D;
 B14-E12; B14-F06; D03-H01T2
 TECH UPTX: 20010126
 TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The **Dextran** preferably has a molecular weight of more than 500000. The composition optionally comprises insulin, fructo-, galacto- or xylo-oligosaccharides, or mixtures thereof and a lipid source rich in monounsaturated fatty acids that is also low in saturated fatty acids.
 ABEX
 ADMINISTRATION. - Taken orally as a nutritional composition or as a food additive. The dose of **dextran** is 2-15 g/day.
 L130 ANSWER 2 OF 3 WPIX (C) 2002 THOMSON DERWENT
 AN 1967-06286G [00] WPIX
 TI Calcium salts of carboxymethyl **dextrans** antihypocalcaemic.
 DC B00 C00
 PA (PHAA) AKTIEBOLAGET PHARMACIA
 CYC 1

PI US 3262847 A (196800)*

PRAI US 1962-240167 19621126

AB US 3262847 A UPAB: 19930831

Water-soluble calcium salts (I) of **carboxymethyldextran** having, on average, 0.5-2.0 carboxymethyl gps. per anhydroglucopyranosic unit, the av. m.wt. of said **dextrans** being is not > 20,000 and pref. 2000-10,000, esp. 2000-5000.

Restricted to (i) method of treating cattle delivery paresis with aq. injectable soln. contng. I (MW **dextran** 2000-5000) and (ii) compn. comprising I (MW **dextran** 2000-5000) together with Ca **propionate** in an aq. injectable soln.

Treatment of Ca deficiency conditions, esp. cattle delivery paresis. Administration is generally by injecting an aq. soln. of I. For treating cattle delivery paresis an aq. soln. contng. both I and Ca **propionate** (II) is pref. I provides a sustained action, whereas II provides the immediate response that is required. This favourable combination of effects is attained without risk to the heart, which may occur if II is used alone.

FS CPI

FA AB

MC CPI: B04-C02; B05-A01B; B12-L09; C04-C02; C05-A01B; C12-L09

L130 ANSWER 3 OF 3 WPIX (C) 2002 THOMSON DERWENT

AN 1966-22170F [00] WPIX

TI Calcium salts of carboxymethyl **dextrans** antihypocalcaemic.

DC B00 C00

PA (PHAA) AKTIEBOLAGET PHARMACIA

CYC 1

PI US 3262847 A (196800)*

PRAI US 1962-240167 19621126

AB US 3262847 A UPAB: 19930831

Water-soluble calcium salts (I) of **carboxymethyldextran** having, on average, 0.5-2.0 carboxymethyl gps. per anhydroglucopyranosic unit, the av. m.wt. of said **dextrans** being is no > 20,000 and pref. 2000-10,000, esp. 2000-5000.

Restricted to (I) method of treating cattle delivery paresis with aq. injectable soln. contng. I (MW **dextran** 2000-5000) and (ii) compn. comprising I (MW **dextran** 2000-5000) together with Ca **propionate** in an aq. injectable soln.

Treatment of Ca deficiency conditions, esp. cattle delivery paresis. Administration is generally by injecting an aq. soln. of I. For treating cattle delivery paresis an aq. soln. contng. both I and Ca **propionate** (II) is pref. I provides a sustained action, whereas II provides the immediate response that is required. This favourable combination of effects is attained without risk to the heart, which may occur if II is used alone.

FS CPI

FA AB

MC CPI: B04-C02; B05-A01B; B12-L09; C04-C02; C05-A01B; C12-L09

=> fil frosti

FILE 'FROSTI' ENTERED AT 09:15:19 ON 14 NOV 2002

COPYRIGHT (C) 2002 Leatherhead Food Research Association

FILE LAST UPDATED: 12 NOV 2002 <20021112/UP>

FILE COVERS 1972 TO DATE.

=> d all tot

L146 ANSWER 1 OF 2 FROSTI COPYRIGHT 2002 LFRA

AN 544888 FROSTI

TI Method for increasing the production of **propionate** in the gastro-intestinal tract.
 IN Jann A.; Arrigoni E.; Rochat F.; Schmid D.
 PA Societe des Produits Nestle SA
 SO European Patent Application
 PI EP 1060673 A1
 AI 19990520
 DT Patent
 LA English
 SL English
 AB A method for increasing the production of **propionate** in the gastro-intestinal tract of mammals is described. **Dextran** may be added to food products to increase the production of **propionate** in the GI tract. Patient compliance is enhanced when the **dextran** is added to a convenience food product. Increasing **propionate** levels decreases blood triglyceride and very-low-density lipoprotein levels, whilst enhancing high-density lipoproteins and insulin sensitivity.
 SH FUNCTIONAL FOODS
 CT BLOOD LIPIDS; BLOOD SERUM; **DEXTRAN**; DIGESTIVE AIDS; DIGESTIVE DISORDERS; EUROPEAN PATENT; FUNCTIONAL FOODS; HIGH DENSITY LIPOPROTEINS; INSULIN SENSITIVITY; LIPOPROTEINS; LOW DENSITY LIPOPROTEINS; PATENT; POLYSACCHARIDES; **PROPIONATES**; PROTEINS; TRIGLYCERIDES
 DED 16 Feb 2001

L146 ANSWER 2 OF 2 FROSTI COPYRIGHT 2002 LFRA
 AN 543990 FROSTI
 TI Method for increasing **propionate** in the gastro-intestinal tract.
 IN Jann A.; Arrigoni E.; Rochat F.; Schmid D.; Bauche A.
 PA Societe des Produits Nestle SA
 SO PCT Patent Application
 PI WO 2000070964 A1 20001130
 AI 20000519
 PRAI European Patent Office 19990520
 NTE 20001130
 DT Patent
 LA English
 SL English
 AB A method is given for increasing the production of **propionate** in the gastrointestinal tract by enterally administering a nutritional composition containing **dextran**. This can also decrease blood triglyceride levels and low-density lipoprotein levels.
 SH FUNCTIONAL FOODS
 CT **DEXTRAN**; DIETARY SUPPLEMENTS; FUNCTIONAL FOODS; GASTROINTESTINAL TRACT; PATENT; PCT PATENT; POLYSACCHARIDES; PREBIOTICS; **PROPIONATES**
 DED 7 Feb 2001

=> d his

(FILE 'HOME' ENTERED AT 07:28:54 ON 14 NOV 2002)
 SET COST OFF

FILE 'REGISTRY' ENTERED AT 07:29:05 ON 14 NOV 2002
 E PROPIONIC ACID/CN

L1	1 S E3
	E PROPIONATE/CN
L2	1 S E3
	E DEXTRAN/CN
L3	1 S E3
L4	2 S L1,L2

SEL RN
 L5 1416 S E1-E2/CRN
 L6 929 S L5 NOT (MNS OR MXS OR IDS OR PMS OR AYS OR CCS)/CI
 L7 530 S L6 NOT COMPD
 L8 331 S L7 NOT SALT
 L9 199 S L7 NOT L8
 L10 15 S L9 AND NR>=1
 L11 184 S L9 NOT L10
 L12 186 S L4,L11
 SEL RN L3
 L13 931 S E3/CRN
 L14 1132 S DEXTRAN
 L15 1134 S L13,L14
 L16 1133 S L15 NOT L3
 E INULIN/CN
 L17 1 S E3
 E FRUCTOSE/CN
 L18 2 S E3
 L19 1 S L-FRUCTOSE/CN
 E GALACTOSE/CN
 L20 2 S E3
 L21 1 S L-GALACTOSE/CN
 E XYLOSE/CN
 L22 2 S E3
 L23 1 S L-XYLOSE/CN

FILE 'HCAPLUS' ENTERED AT 07:47:22 ON 14 NOV 2002

L24 19794 S L4
 L25 2929 S L11
 L26 68956 S PROPIONIC ACID OR PROPIONATE
 L27 5679 S PROPAANOIC ACID
 L28 78352 S L24-L27
 L29 11735 S L3
 L30 7546 S L16
 L31 30359 S DEXTRAN
 L32 31947 S ?DEXTRAN?
 L33 33493 S L29-L32
 L34 158 S L28 AND L33

FILE 'REGISTRY' ENTERED AT 07:50:44 ON 14 NOV 2002

L35 1 S CHOLESTEROL/CN

FILE 'HCAPLUS' ENTERED AT 07:50:48 ON 14 NOV 2002

L36 85119 S L35
 L37 153391 S ?CHOLESTER?
 L38 10311 S HYPERLIPID? OR HYPERLIPEM? OR HYPERLIPAEM?
 L39 28640 S TRIGLYER? OR VLDL OR HDL OR LIPOPROTEIN(L) (VLD OR HD OR VERY

FILE 'REGISTRY' ENTERED AT 07:53:24 ON 14 NOV 2002

L40 1 S INSULIN/CN
 L41 6338 S INSULIN NOT L40

FILE 'HCAPLUS' ENTERED AT 07:53:33 ON 14 NOV 2002

L42 101061 S L40 OR L41
 L43 148034 S ?INSULIN?

FILE 'REGISTRY' ENTERED AT 07:53:52 ON 14 NOV 2002

L44 2 S GLUCOSE/CN

FILE 'HCAPLUS' ENTERED AT 07:53:58 ON 14 NOV 2002

L45 133720 S L44
 L46 342761 S GLUCOSE
 L47 35 S L34 AND L36-L39,L42,L43,L45,L46

L48 33393 S LIPOPROTEIN(L) (VERY () (LOW DENSITY OR LOW DEN OR L DENSITY OR
 L49 1 S L34 AND L48
 L50 35 S L47, L49
 L51 2 S L3 (L) FFD/RL AND L50
 L52 2 S L50 AND NUTRI?/SC, SX
 L53 12 S L50 AND (L17-L23 OR INULIN OR ?FRUCTO? OR ?GALACTO? OR ?XYLO?
 E SACCHARIDE/CT
 E E4+ALL
 L54 1628 S E1
 E E3+ALL
 L55 7563 S E3
 E E4+ALL
 E E4+ALL
 L56 26460 S E4, E3, E18, E37, E38, E64
 E E5+ALL
 E E5+ALL
 L57 39306 S E3
 L58 12 S L50 AND L54-L57
 L59 20 S L51-L53, L58
 L60 3 S L59 AND FATTY ACID
 L61 3 S L59 AND LIPID
 L62 4 S L60, L61
 SEL DN AN 2 3
 L63 2 S L62 AND E1-E6
 L64 31 S L50 NOT L62
 SEL DN AN 4 31
 L65 2 S L64 AND E7-E12
 L66 4 S L63, L65 AND L24-L34, L36-L39, L42, L43, L45-L65
 L67 3 S L34 AND TRIGLYCER?
 L68 1 S L67 AND GASTRO INTESTINAL TRACT
 L69 4 S L66, L68
 E JANN A/AU
 L70 13 S E3, E5
 E ARRIGONI E/AU
 L71 117 S E3, E8, E9
 E ROCHAT F/AU
 L72 19 S E3-E5, E7
 E SCHMID D/AU
 L73 160 S E3-E15
 E BAUCHE A/AU
 L74 4 S E3, E5
 E NESTLE/PA, CS
 L75 2322 S E3, E4
 L76 2325 S NESTLE?/PA, CS
 L77 1 S L50 AND L70-L76
 L78 4 S L69, L77
 L79 4165 S L28 AND (GASTROINTESTIN? OR GASTRO INTESTIN? OR ?INTESTIN? OR
 E GASTROINTESTIN/CT
 E E30+ALL
 E E2+ALL
 L80 551727 S E3+NT
 L81 4420 S E102+NT OR E106+NT
 E GASTROINTESTIN/CT
 E E9+ALL
 L82 3886 S E2
 E ANTICHOLESTEROL/CT
 E E4+ALL
 E E2+ALL
 L83 8108 S E5, E6, E4+NT
 L84 3567 S L28 AND L80-L83
 L85 6169 S L79, L84
 L86 319 S L85 AND CARBOHYDRATE?/SC, SX, CW
 L87 2153 S L28 AND L36-L39, L42, L43

L88 74 S L87 AND CARBOHYDRATE?/SC, SX, CW
 L89 12 S L86, L87 AND L33
 L90 3 S L89 AND L78
 L91 9 S L89 NOT L90
 L92 34 S L85, L87 AND L33
 L93 19 S L92 NOT L50
 SEL DN AN 12
 L94 1 S E1-E3 AND L93
 L95 5 S L78, L90, L94
 SEL HIT RN

FILE 'REGISTRY' ENTERED AT 08:34:16 ON 14 NOV 2002
 L96 8 S E4-E11

FILE 'REGISTRY' ENTERED AT 08:34:42 ON 14 NOV 2002

FILE 'HCAPLUS' ENTERED AT 08:34:58 ON 14 NOV 2002

FILE 'MEDLINE' ENTERED AT 08:35:21 ON 14 NOV 2002
 L97 18017 S L28
 E PROPIONATE/CT
 E E5+ALL
 L98 5614 S E21/CT, CN
 L99 3011 S E26/CT, CN
 L100 18017 S L97-L99
 L101 15674 S L3
 E DEXTRAN/CT
 E E3+ALL
 E E2+ALL
 L102 14655 S E21/CT, CN
 L103 19 S L100 AND L101, L102
 L104 41 S L100 AND ?DEXTRAN?
 L105 41 S L103, L104
 E 34 38 40 AB
 L106 9 S L105 AND (A3. OR C6.)/CT
 L107 1 S L105 AND C18./CT
 L108 9 S L106, L107
 L109 8 S L108 NOT DEXTRAN SODIUM SULFATE
 L110 7 S L109 NOT DEXTRAN SULFATE SODIUM
 L111 6 S L110 NOT DEXTRAN SULFATE
 SEL DN AN 2 6
 L112 2 S L111 AND E1-E6

FILE 'MEDLINE' ENTERED AT 08:58:41 ON 14 NOV 2002

FILE 'WPIX' ENTERED AT 08:58:53 ON 14 NOV 2002
 L113 16697 S L26 OR L27 OR R00445/DCN OR 0445/DRN
 L114 113 S C07C053-122/IC, ICM, ICS, ICA, ICI
 L115 16747 S L113, L114
 L116 14003 S ?DEXTRAN? OR V721/M0, M1, M2, M3, M4, M5, M6 OR R01857/DCN OR 1857/
 L117 104 S L115 AND L116
 L118 5 S L117 AND A23?/IC, ICM, ICS, ICA, ICI
 L119 2 S L117 AND D03-H01T?/MC
 L120 .5 S L117 AND (B14-F06 OR C14-F06 OR B12-H03 OR C12-H03 OR B14-E12
 L121 5 S L117 AND (P814 OR P816)/M0, M1, M2, M3, M4, M5, M6
 E R16573+ALL/DCN
 L122 462 S E1
 E R01851+ALL/DCN
 E R06675+ALL/DCN
 L123 10 S L122 AND L115
 L124 0 S L123 NOT L117
 L125 10 S L118-L121
 L126 1 S L123 AND L125

L127 • 9 S L123 NOT L126
L128 85 S L117, L123 NOT L118-L121, L123-L127
 SEL DN AN 83 84
L129 2 S L128 AND E1-E2
L130 3 S L126, L129 AND L113-L129

FILE 'WPIX' ENTERED AT 09:11:28 ON 14 NOV 2002

FILE 'FSTA' ENTERED AT 09:11:42 ON 14 NOV 2002
L131 1823 S L26 OR L27
L132 875 S DEXTRAN OR OLIGODEXTRAN
 E DEXTRAN/CT
 E E3+ALL
L133 205 S E5
 E PROPION/CT
L134 40 S E11, E21
 E E43+ALL
L135 407 S E5
 E PROPANOIC/CT
L136 1 S E4
L137 2 S L131, L134-L136 AND L132, L133

FILE 'FROSTI' ENTERED AT 09:13:31 ON 14 NOV 2002

L138 1113 S L131
 E PROPANOIC/CT
L139 1 S E4
 E PROPIONIC/CT
L140 397 S E5
 E PROPIONATE/CT
 E E4+ALL
L141 106 S E1
L142 397 S E2+NT
L143 1113 S L138-L142
L144 517 S L132
 E DEXTRAN/CT
 E E3+ALL
L145 263 S E4
L146 2 S L143 AND L144, L145

FILE 'FROSTI' ENTERED AT 09:15:19 ON 14 NOV 2002